Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
My previous session
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 1 300 B
EBIT 2019 272 B
Net income 2019 209 B
Finance 2019 402 B
Yield 2019 2,05%
Sales 2020 1 275 B
EBIT 2020 212 B
Net income 2020 191 B
Finance 2020 480 B
Yield 2020 2,12%
P/E ratio 2019 17,44
P/E ratio 2020 19,11
EV / Sales2019 2,56x
EV / Sales2020 2,55x
Capitalization 3 727 B
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
08/17ASTELLAS PHARMA : Announces Acquisition of Quethera
AQ
08/16ASTELLAS PHARMA : Findings on Cancer Therapy Reported by Investigators at Astell..
AQ
08/16ASTELLAS PHARMA : Researchers at Astellas Pharma Report New Data on Lower Urinar..
AQ
08/16ASTELLAS PHARMA : acquires Quethera for $108.5m
AQ
08/14ASTELLAS PHARMA : buys eye gene therapy biotech Quethera for $109m
AQ
08/13ASTELLAS PHARMA : acquires ophthalmic company Quethera
AQ
08/11ASTELLAS PHARMA : Acquires Quethera
AQ
08/11ASTELLAS PHARMA : absorbs U.K. ocular gene therapy player Quethera
AQ
08/10ASTELLAS PHARMA : Announces Acquisition of Quethera - Acquisition furthers &rsqu..
PU
08/09ASTELLAS PHARMA : Findings from Astellas Pharma Provides New Data on Extracellul..
AQ
More news
Sector news : Pharmaceuticals - NEC
04:08pEUROPE MARKETS: Bayer And Oil Shares Lead Gains For European Stock Benchmarks
DJ
01:03pALEXION : FDA Accepts Priority Review of ALXN1210 in Blood Disorder
DJ
08:27aROCHE : Alecensa latest beneficiary of faster China drug approvals
RE
07:30aRoche's Alecensa Gets Green Light From China National Drug Administration
DJ
08/18ASTRAZENECA : Biopharma Spinout Entasis Files for IPO
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
08/14missed this one last week Astellas Announces Acquisition of Quethera for £85m.. 
08/13Astellas buys UK group Quethera
2
08/10#2 Astellas grabs a biotech toddler in $109M buyout deal for a glaucoma gene.. 
08/10Astellas Pharma adds ocular gene therapy tuck-in Quethera for potential £85M .. 
08/10Astellas absorbs U.K. ocular gene therapy player Quethera  
More tweets
Qtime:32
News from SeekingAlpha
08/10Astellas acquires UK-based gene therapy developer for up to £85M 
07/30Astellas Pharma, Inc. ADR 2018 Q1 - Results - Earnings Call Slides 
07/163 THINGS IN BIOTECH, JULY 16 : Array Gets An Important Update 
07/13FDA OKs expanded use for prostate cancer med Xtandi 
07/13Key events next week - healthcare 
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 827  JPY
Spread / Average Target -3,0%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda General Manager-Pharmaceutical Technology
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC29.83%33 715
JOHNSON & JOHNSON-3.76%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY22.73%183 667